TOP TEN perturbations for 41514_s_at (Homo sapiens)

Organism: Homo sapiens
Gene: 41514_s_at
Selected probe(set): 209609_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 41514_s_at (209609_s_at) across 6673 perturbations tested by GENEVESTIGATOR:

Alzheimer's disease study 6 / normal large stellate neuron (entorhinal cortex)

Relative Expression (log2-ratio):-2.3350859
Number of Samples:10 / 12
Experimental Alzheimer's disease study 6
Large stellate neurons of the entorhinal cortex, collected from layer II of clinically and neuropathologically classified late-onset Alzheimer´s disease afflicted individuals. Subjects in this group had a Braak stage of V or VI with a CERAD score of moderate or frequent.
Control normal large stellate neuron (entorhinal cortex)
Large stellate neurons of the entorhinal cortex, collected from layer II of clinically classified as neurologically normal individuals. Subjects in this group had a Braak stage ranging from I to II with a infrequent Consortium to Establish a Registry for Alzheimer's Disease (CERAD) neuritic plaque density.

pediatric septic shock study 3 (infant; subclass A) / normal blood sample (infant)

Relative Expression (log2-ratio):-2.1568766
Number of Samples:8 / 17
Experimental pediatric septic shock study 3 (infant; subclass A)
Whole blood samples obtained from infants (1 month – 1 year) with septic shock subclass A. The samples were obtained within 24 hours of admission to the pediatric intensive care unit. Two children did not survive. The subclass A was defined based on an empiric, discovery oriented expression filter and unsupervised hierarchical clustering. Patients in subclass A (when all age groups were pooled) had a significantly higher illness severity level (PRISM III score = 20.5, intra-quartile range (IQR) 12.5 – 32.5), a greater degree of organ failure – maximum number of organ failures 3 (IQR 3 - 4), and a higher mortality rate, a significantly higher incidence of documented Gram-positive bacterial infection and were significantly younger compared with other subclasses.
Control normal blood sample (infant)
Whole blood samples from infants (1 month – 1 year). Children who had a recent febrile illness (within 2 weeks), who recently used anti-inflammatory medications (within 2 weeks) or who had any history of chronic or acute disease associated with inflammation were excluded from the study.

breast cancer study 3 / normal organelle sample

Relative Expression (log2-ratio):2.052947
Number of Samples:17 / 12
Experimental breast cancer study 3
Breast basal tumor samples.
Control normal organelle sample
Normal organelle samples.

glioma study 17 (glioblastoma; unsorted) / non-tumor cortical tissue

Relative Expression (log2-ratio):1.9586468
Number of Samples:2 / 4
Experimental glioma study 17 (glioblastoma; unsorted)
Brain cells isolated from high grade glioblastoma (grade IV). Tumor tissue was dissociated using enzymatic treatment and all cells were used for RNA isolation.
Control non-tumor cortical tissue
Cortical tissue obtained from patients with epilepsy, but without any manifested brain cancer. The tissue was dissociated using enzymatic treatment, but all brain cell types were used for analyses.

T-cell activation study 4 / normal resting T-cell sample

Relative Expression (log2-ratio):1.9161415
Number of Samples:2 / 2
Experimental T-cell activation study 4
T-cell samples antiCD3 activated for 30hrs.
Control normal resting T-cell sample
T cells resting for 30h.

expO breast cancer study 1 (mucocarcinoid tumor, malignant; primary) / expO breast cancer study 1 (medullary carcinoma, NOS; primary)

Relative Expression (log2-ratio):-1.9073343
Number of Samples:6 / 2
Experimental expO breast cancer study 1 (mucocarcinoid tumor, malignant; primary)
Primary tumor tissue samples obtained from the breast of patients with malignant mucocarcinoid tumor.
Control expO breast cancer study 1 (medullary carcinoma, NOS; primary)
Primary tumor tissue samples obtained from the breast of patients with medullary carcinoma (NOS).

R547 study 1 (24h) / vehicle (DMSO) treated DU145 cell sample

Relative Expression (log2-ratio):-1.8811417
Number of Samples:2 / 4
Experimental R547 study 1 (24h)
Human prostate carcinoma metastatic cell line DU145 treated with the CDK inhibitor R547 [4-amino-2-(1-methanesulfonylpiperidin-4-ylamino) pyrimidin-5-yl]-(2, 3-difluoro-6-methoxyphenyl)methanone (Hoffmann-La Roche compound) for 24 hours at a 3xIC90 concentration of 5.1 μmol/L. ATC code:---
Control vehicle (DMSO) treated DU145 cell sample
Human prostate carcinoma metastatic cell line DU145 treated with vehicle (DMSO) for 24 hours.

glioma study 17 (anaplastic astrocytoma; A2B5+) / non-tumor oligodendrocyte progenitor cell sample (cortex)

Relative Expression (log2-ratio):1.8752022
Number of Samples:2 / 3
Experimental glioma study 17 (anaplastic astrocytoma; A2B5+)
Oligodendrocyte progenitor cells (OPC) isolated from high grade anaplastic astrocytoma (grade III). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 45 ± 18 years old.
Control non-tumor oligodendrocyte progenitor cell sample (cortex)
Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen.

vMyb overexpr. study 1 (adenovirus) / cMyb overexpr. study 2 (adenovirus)

Relative Expression (log2-ratio):-1.8565607
Number of Samples:2 / 2
Experimental vMyb overexpr. study 1 (adenovirus)
Approximately 1x10^6 monocytes were infected with adenovirus expressing v-Myb and GFP for 16 hours, then total RNA was isolated.
Control cMyb overexpr. study 2 (adenovirus)
Approximately 1x10^6 monocytes were infected with adenovirus expressing c-Myb and GFP for 16 hours, then total RNA was isolated.

pediatric septic shock study 3 (infant; subclass C) / pediatric septic shock study 3 (infant; subclass A)

Relative Expression (log2-ratio):1.8238649
Number of Samples:9 / 8
Experimental pediatric septic shock study 3 (infant; subclass C)
Whole blood samples obtained from infants (1 month – 1 year) with septic shock subclass C. The samples were obtained within 24 hours of admission to the pediatric intensive care unit. All children survived. The subclass C was defined based on an empiric, discovery oriented expression filter and unsupervised hierarchical clustering. Patients from subclass C (when all age groups were pooled) had an illness severity level (PRISM III score) 15 (intra-quartile range (IQR) 10.7 - 19.2), maximum number of organ failures 2 (IQR 2 - 2), and a low mortality rate.
Control pediatric septic shock study 3 (infant; subclass A)
Whole blood samples obtained from infants (1 month – 1 year) with septic shock subclass A. The samples were obtained within 24 hours of admission to the pediatric intensive care unit. Two children did not survive. The subclass A was defined based on an empiric, discovery oriented expression filter and unsupervised hierarchical clustering. Patients in subclass A (when all age groups were pooled) had a significantly higher illness severity level (PRISM III score = 20.5, intra-quartile range (IQR) 12.5 – 32.5), a greater degree of organ failure – maximum number of organ failures 3 (IQR 3 - 4), and a higher mortality rate, a significantly higher incidence of documented Gram-positive bacterial infection and were significantly younger compared with other subclasses.